Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Controlled, Multiple Dose, Safety, Pharmacokinetic, and Pharmacodynamic Study of PLS240 in Pediatric Participants 1 Month to <18 Years of Age With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Maintenance Hemodialysis

NCT07890584 is registered in ClinicalTrials.gov with Pathalys Pharma as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07890584 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Controlled, Multiple Dose, Safety, Pharmacokinetic, and Pharmacodynamic Study of PLS240 in Pediatric Participants 1 Month to <18 Years of Age With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Maintenance Hemodialysis
Lead sponsor
Pathalys Pharma
Phase
Phase 3
Overall status
Not yet recruiting
Start date
October 30, 2026
Completion date
February 22, 2032
Enrollment
56 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease (ckd), secondary hyperparathyroidism

Arms

As registered; 3 arms.

  • Cohort 1 ExperimentalPLS240, Standard of Care

    Adolescents aged ≥13 to \<18 years. The study will initially only recruit participants into the older age group (Cohort 1). Participants will receive PLS240 plus standard of care.

  • Cohort 2 ExperimentalPLS240, Standard of Care

    Children aged 1 month to \<13 years. Once safety and Pharmacokinetic (PK)/Pharmacodynamic (PD) data from 15 evaluable participants from Cohort 1 have been reviewed by a Safety Review Committee (SRC), recruitment into the younger (infants, toddlers, and children) age group will commence. Participants will receive PLS240 plus standard of care.

  • Control Group Active comparatorStandard of Care

    Participants will only receive standard of care

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Incidence of treatment-emergent adverse events (TEAEs). From the first dialysis session after randomization and up to 28 days after the last administration of study medication for participants receiving PLS240 and up to Week 32 for participants in the control group.

Lead sponsor's other trials

Pathalys Pharma, most recent start first.

Similar trials

Same condition (Hyperparathyroidism, Secondary) and phase, most recent start first.